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Objective. Quantitative ultrasound (QUS) provides an estimate of bone mineral density (BMD) and also evaluates bone quality,
which has been related to increased fracture risk in people with diabetes. This study aimed at assessing the correlates of
calcaneal QUS parameters in diabetic subjects encompassing various degrees of micro and macrovascular complications and a
wide-range of peripheral nerve function. Methods. Four hundred consecutive diabetic patients were examined by QUS to obtain
values of broadband ultrasound attenuation (BUA), the speed of sound (SOS), quantitative ultrasound index (QUI), and BMD.
Results. Among surrogate measures of complications, sensory and motor nerve amplitude and heart rate response to cough test
and standing correlated with QUS parameters at univariate analysis, together with age, body mass index (BMI), waist
circumference, lipid profile, and renal function. Multivariate analysis revealed that BUA, SOS, QUI, and BMD were
independently associated with age, male gender, hemoglobin A1c, BMI (or fat, but not fat-free mass), and somatic and
autonomic nerve function parameters. Conclusions. These data indicate that peripheral nerve dysfunction is associated with
worse QUS parameters, possibly contributing to increased fracture risk in diabetes. The positive relation of QUS measures with
adiposity needs further investigation. This trial is registered with ClinicalTrials.gov (NCT01600924).
1. Introduction
It is now widely recognized that diabetes mellitus (DM) is
associated with an increased risk of fractures, which seems
to be dependent on mechanisms at least partly differing from
those associated with senile or postmenopausal osteoporosis
[1]. A meta-analysis of 16 studies showed a relative risk for
hip fractures of 6.94 in type 1 DM (T1DM) and 1.38 in type
2 DM (T2DM) compared to subjects without DM [2]. Inter-
estingly, bone mineral density (BMD), the strongest predic-
tor of fractures in subjects with osteoporosis [3], was found
to be reduced in patients with T1DM in most, but not all
studies, whereas cross-sectional surveys in subjects with
T2DM reported normal or even increased BMD, despite
the overall increase in fracture risk [2]. Moreover, increased
fracture risk in T2DM patients remained after adjustment
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for BMD [4–6] and also for falls [4, 6, 7], which are more fre-
quent in older individuals with T2DM than in their nondia-
betic counterparts [8]. While the lower fracture risk in T2DM
versus T1DM may be explained by the normal-to-increased
bone mass, the apparent discrepancy between preserved
BMD and increased fracture risk in individuals with T2DM
and the higher fracture risk than that estimated from BMD
variation in subjects with T1DM have prompted the hypoth-
esis that DM patients have reduced bone quality [1, 2].
Bone quality is determined by (a) bone architecture,
including geometry (macroarchitecture) and microarchitec-
ture, and (b) material properties, including mineralization
and collagen cross-links, which in turn are influenced by
bone turnover as well as by accumulation of microdamage
and microstructural discontinuities such as microporosity
and lamellar boundaries [9]. Several factors have been
claimed to affect bone quality (and mass) in DM, mainly by
reducing bone turnover [10]. The advanced glycation end-
products (AGEs) cause the formation of collagen cross-links,
which negatively correlate with material properties, in addi-
tion to adversely affecting bone metabolism via receptor-
mediated mechanisms [11]. Moreover, the long-term,
microvascular, and macrovascular complications have been
hypothesized to contribute to impaired bone turnover in
T1DM and T2DM patients, consistent with the role of vessels
[12] and nerves [13] in bone metabolism, and also to favor
falls and injury in a fall [14]. In fact, diabetic peripheral neu-
ropathy (DPN) is also an independent risk factor for reduced
BMD in the affected limbs [15] and increases the risk of falls
by affecting balance and gait [16], thus leading to increased
fracture risk [17]. Likewise, the reduction of muscle strength,
mass, and quality associated with DM [18] cause not only
reduced mechanical strain on the skeleton resulting in
reduced bone mass, according to the mechanostat theory
[19], but also poor physical performance and reduced mobil-
ity favoring falls [20]. In contrast, the impact of hyperinsuli-
nemia and increased body mass index (BMI) associated with
T2DM is controversial. On the one hand, they may favor
bone formation through direct anabolic effects [21] and
increased mechanical load [22], respectively. On the other
hand, the low-grade inflammation accompanying insulin
resistance can exert detrimental effects on the skeleton [23]
and insulin resistance may suppress bone turnover indepen-
dently of adiposity [24].
Quantitative ultrasound (QUS), which is performed
mainly at the heel, provides an estimate of BMD, thus
reflecting bone mass [25]. Assessment of estimated BMD
(eBMD) by QUS confirmed the increase in BMD detected
by dual-energy X-ray absorptiometry (DXA) in patients
with T2DM [26]. In older women with T2DM, QUS pre-
dicted fracture risk better than DXA [26], though, just like
DXA-derived BMD, it failed to identify T2DM subjects
with vertebral fractures [27]. In addition, QUS evaluates
parameters of bone quality, including microarchitecture
and material properties [28, 29].
This study was aimed at assessing the correlates of calca-
neal QUS parameters in subjects with T1DM and T2DM,
encompassing various degrees of micro- and macrovascular
complications and a wide-range of peripheral nerve function.
2. Subjects and Methods
2.1. Patients. In this cross-sectional analysis, we used the data
collected at the baseline visit for the Study on the Assessment
of Determinants of Muscle and Bone Strength Abnormalities
in Diabetes (SAMBA), an observational, prospective cohort
study on the independent predictors of loss of muscle and
bone strength in patients with T1DM and T2DM. The study
was conducted in accordance with the 1964 Declaration of
Helsinki and its later amendments. The research protocol
was approved by the locally appointed ethics committee,
and participants gave written informed consent.
The SAMBA cohort included 400 patients, 80 with
T1DM and 320 with T2DM, who attended consecutively
an outpatient diabetes clinics for the screening of compli-
cations in years 2008–2011. Patients who were unable to
correctly perform the test procedures were excluded from
the study [30].
2.2. Measurements
2.2.1. Calcaneal QUS.QUS measurements were performed at
the heel using the Sahara® Clinical Bone Sonometer (Hologic
Inc., Waltham, MA, USA).
Broadband ultrasound attenuation (BUA; in dB/MHz)
and speed of sound (SOS; in m/s) were measured, and the
quantitative ultrasound index (QUI) or stiffness index (SI)
was calculated from them and expressed as absolute values
and T- and Z-scores. In turn, eBMD (g/cm2) was derived
from QUI [25, 26] and expressed as absolute values and T-
and Z-scores.
2.2.2. Cardiovascular Risk Factors. All patients underwent a
structured interview in order to collect the following infor-
mation: demographics, lifestyle habits, known DM duration,
and current treatments.
Physical activity (PA) level was assessed using theMinne-
sota Leisure-Time PA questionnaire [30]. Patients were then
classified as sedentary (i.e., ≥8 hours/day spent in any waking
behavior characterized by an energy expenditure≤ 1.5 meta-
bolic equivalents (METs) while in a sitting or reclining
posture), physically inactive (i.e., not engaged in any physical
activity during the week), or physically active (i.e., low
PA [<3.5 METs·h−1·week−1], moderate PA [3.5–10
METs·h−1·week−1], or high PA [>10 METs·h−1·week−1]).
Cardiorespiratory fitness was assessed by measuring maxi-
mal oxygen consumption (VO2max) at the treadmill, using
a modified Balke and Ware protocol, with direct measure-
ment of oxygen consumption using the gas exchange
analyzer (FitMate, Cosmed, Rome, Italy). Muscle strength
was assessed in isometric conditions by means of a Digimax
electronic dynamometer (Mechatronic GmbH, Germany),
as previously described [30].
BMI was calculated from body weight and height, waist
circumference was measured at the umbilicus, and fat mass
and fat-free mass were assessed by body impedance (Tanita
BF664, Vernon Hills, IL, USA). Blood pressure (BP) was
measured with a mercury sphygmomanometer with the
patients seated with the arm at the heart level. Hypertension
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was defined by systolic BP≥ 140mmHg and/or diastolic
BP≥ 90 and/or antihypertensive treatment.
Hemoglobin- (Hb-) A1c was assessed by a DCCT-aligned
high-performance liquid chromatography method (Adams
TMA1C HA-8160, Menarini Diagnostics, Florence, Italy).
Fasting glucose, triglycerides, total and HDL cholesterol,
nitrogen, and uric acid were measured by standard analytical
methods using the VITROS 5.1 FS Chemistry System
(Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA), and
LDL cholesterol was calculated by the Friedewald formula.
2.2.3. Complications. Prevalent cardiovascular disease (CVD)
was assessed from medical history by recording previous
documented major acute CVD events, including myocardial
infarction, stroke, foot ulcer, gangrene and amputation, and
revascularization procedures [31]. In addition, carotid
intima-media thickness (IMT) and ankle-brachial index
(ABI) were assessed as surrogate measures of diabetic macro-
angiopathy by color-coded duplex sonography (Agilent HP
ImagePoint HX, Hewlett Packard, Rome, Italy) and a mer-
cury sphygmomanometer plus a handheld continuous wave
Doppler device (Super Doppler 2, Huntleigh Healthcare,
Lewis Center, OH), respectively.
Diabetic nephropathy was evaluated by assessing serum
creatinine and albuminuria. Serum creatinine was measured
by the modified Jaffe method, and estimated glomerular
filtration rate (eGFR) was calculated by the chronic kidney
disease epidemiology collaboration (CKD-EPI) equation
(http://www.qxmd.com/calculate-online/nephrology/ckd-epi-
egfr). Albuminuria was assessed as albumin : creatinine ratio
(ACR) by measuring albumin and creatinine concentration
by immunonephelometry and the modified Jaffe method,
respectively, in first-morning, urine samples. Patients were
then assigned to one of the following categories of eGFR
(ml/min/1.73m2): 1 (≥90), 2 (60–89), 3a (45–59), 3b
(30–44), 4 (15–29), and 5 (<15), and albuminuria (mg/g):
normoalbuminuria (<30), including normal (<10) and low
(<10–29) albuminuria, microalbuminuria (30–299), and
macroalbuminuria (≥300) [32]. As previously reported [33],
patients were classified according to the National Kidney
Foundation’s Kidney Disease Outcomes Quality Initiative
as having no CKD, albuminuria alone (stages 1-2 CKD),
reduced eGFR alone (stage≥ 3 CKD without albuminuria),
or both (stage≥ 3 CKD with albuminuria).
Diabetic retinopathy (DR) was evaluated by fundus
examination in mydriasis. Patients were classified into the
following categories: absent DR, mild, moderate or severe
nonproliferative DR, proliferative DR, or maculopathy. For
further analysis, patients with mild or moderate nonproli-
ferative DR were classified as having nonadvanced DR,
whereas those with severe nonproliferative DR, proliferative
DR, maculopathy, or blindness were grouped into the
advanced, sight-threatening DR category [34].
Definition of DPN was based on symptoms, signs, and
neuroelectrophysiological abnormalities according to the
Toronto Diabetic Neuropathy Expert Group and further
classified in classical symmetrical polyneuropathy, focal or
multifocal neuropathy, or DM-associated neuropathy such
as chronic inflammatory demyelinating polyneuropathy
[35]. Symptoms and signs of DPN were assessed using the
Michigan neuropathy screening instrument (MNSI) com-
prising a 15-item self-administered questionnaire and a
lower extremity examination that includes foot inspection,
assessment of vibration perception threshold (VPT) at hallux
and ankle reflexes, and monofilament testing (http://www.
med.umich.edu/borc/profs/documents/svi/MNSI_patient.
pdf). The VPT in the left and right malleolus and hallux
was assessed by the use of both a diapason and a biothe-
siometer (Horwell, Nottingham, UK). The distal latencies,
amplitudes, and conduction velocities of the peroneal motor
nerve (PMN) and sural sensory nerve (SSN) were measured
bilaterally by electromyography (EMG), using a Medelec
MS 928 Neurostar (Oxford Instruments Medical, Old Wok-
ing, UK), and results were compared with age-related refer-
ence values [36]. Patients were then stratified for severity of
DPN using an arbitrary score calculated as the sum of the
individual scores for symptoms (0 to 13, based on the MNSI
questionnaire, not considering answers to questions 4 and
10), signs (0 to 10, based on the MNSI lower extremity exam-
ination), and EMG data (0 to 12, based on distal latencies,
amplitudes, and conduction velocities of sural and peroneal
nerves of the two legs).
Autonomic function was assessed by resting heart
rate (HR), as a surrogate index, and cardiovascular auto-
nomic reflex tests (CARTs) [37], that is, HR response to
deep breathing (beat-to-beat variation and expiration-to-
inspiration (EI) ratio), cough test (CT ratio), and standing
(30 : 15 ratio), and systolic BP response to standing (supine-
standing BP). According to age-related reference values
[38], each test was scored as follows: 0 =normal; 1 = border-
line, and 2= abnormal. Subjects were then stratified for
cardiac autonomic neuropathy (CAN) based on the sum
of the scores assigned to each CART (CAN score).
Maximal voluntary contractions (MVCs) were per-
formed at the shoulder press (Technogym, Gambettola, Italy)
along the sagittal plan, with a 45° and 90° angle at the elbow
and between the upper arm and the trunk, respectively, for
the upper body, and at the leg extension machine (Techno-
gym), with a 90° angle at the knee and the hip, for the lower
body [30].
2.3. Statistical Analysis. Data are expressed as mean± SD, for
continuous variables, and number of cases and percentages
for categorical variables. Patients were stratified by age, gen-
der, type of diabetes, PA level, complications, and treatments,
and QUS values were compared using the following statisti-
cal tests: the Student t-test for parametric or the correspond-
ing Mann–Whitney U test for nonparametric continuous
variables and the χ2 test for categorical variables.
Univariate analysis of correlations between QUS param-
eters and the variables tested was performed using Spear-
man’s rho. Then, linear regression analyses with stepwise
variable selection were applied to assess independent corre-
lates of QUS parameters. Covariates were age, gender, PA
level, type and duration of DM, HbA1c, BMI (or fat mass
and fat-free mass or height and weight), muscle strength,
and Vo2max plus surrogate measures of complications (model
1) or the presence/absence of CVD, DR and CKD and DPN
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and CAN scores (model 2). The analyses were conducted
both in the whole cohort and separately in T1DM and
T2DM patients.
3. Results
The clinical characteristics of study subjects are reported
in Table 1. Males were more frequently former or current
smokers and physically active and had higher VO2max
(only T2DM), muscle strength, fat-free mass, waist circum-
ference, and lower BMI, fat mass, and HDL cholesterol, as
compared with females. While no gender difference was
observed in the prevalence of nephropathy, retinopathy,
and neuropathy (though there was a significantly different
distribution across CKD phenotypes and categories of
somatic neuropathy), CVD was more frequent in males than
in females.
As previously reported [30], patients with T2DM from
the SAMBA cohort had older age, shorter DM duration,
lower PA level, VO2max, and upper and lower body strength,
as compared with subjects with T1DM. In addition, T2DM
patients had lower HbA1c, total and HDL cholesterol,
eGFR, and ABI, and higher BMI, fat mass, fat-free mass,
waist circumference, triglycerides, systolic and diastolic
BP, uric acid, nitrogen, ACR, and IMT. Prevalence of
CVD and CKD was higher in T2DM patients, whereas ret-
inopathy and somatic neuropathy were more frequent in
T1DM subjects (Supplementary Table 1 available online
at https://doi.org/10.1155/2017/4749619).
All QUS parameters were higher in males than in
females but did not differ between T1DM and T2DM
patients, except for QUI- and eBMD-derived Z-scores,
which were similar in women and men and lower in individ-
uals with T1DM than in those with T2DM (Table 2). All
QUS parameters, except SOS, decreased significantly with
age quartiles (not shown), whereas they increased signifi-
cantly when stratified according to BMI categories (Supple-
mentary Table 2). In addition, there was a nonsignificant
trend towards an increase in BUA, SOS, QUI, and eBMD
values with increasing ACR and a significant decrease with
decreasing eGFR and increasing severity of DR, DPN, and
CAN, but not CVD (data not shown).
At univariate analysis, QUS parameters were strongly
associated between each other and with upper and lower
body strength, cardiorespiratory fitness, BMI, fat-free
mass, waist circumference, triglycerides (except SOS), uric
acid, and, inversely, age and HDL cholesterol, but not total
and LDL cholesterol, BP, and nitrogen, whereas HbA1c
correlated with SOS and DM duration with BUA and
QUI only. Among measures of complications, eGFR, albu-
minuria, ABI, PMN amplitude, SSN distal latency and
amplitude, and HR response to cough test and standing
correlated with some or all QUS parameters (Table 3).
When patients were analyzed separately according to the
type of DM, QUS parameters were found to correlate sig-
nificantly with age, muscle strength, fat-free mass, eGFR,
SSN amplitude, and HR response to cough test and stand-
ing in T1DM patients and with age, muscle strength, BMI,
fat-free mass, waist circumference, HbA1c, triglycerides, HDL
cholesterol, uric acid, serum creatinine, albuminuria, ABI,
SSN amplitude, and HR response to standing, in T2DM
patients (not shown).
Multivariate analysis revealed that BUA, SOS, QUI, and
eBMD were independently associated with age, male gender,
BMI, HbA1c (for SOS and eBMD only), and the following
somatic and autonomic nerve function parameters (model
1): PMN and SSN amplitude, VPT hallux (for BUA and
eBMD only), HR response to cough test (CT ratio, for eBMD
only) and standing (30 : 15, for QUI and eBMD only), and,
inversely, resting HR (for SOS and eBMD only). Conversely,
the type and duration of DM, muscle strength, Vo2max, eGFR,
carotid IMT, ABI, and CARTs did not enter the model. In
patients with T1DM, age, male gender, BMI, PMN and SSN
amplitude, VTP allux, and HR response to cough test and
standing (for eBMD only), but not HbA1c and resting HR,
were independently associated with QUS measures. In
individuals with T2DM, correlates of QUS parameters were
similar, except for HbA1c and resting HR, which were signif-
icantly associated with QUS measures, VPT hallux and HR
response to standing, which were not, and HR response to
cough test, which was independently associated with SOS
instead of eBMD (Table 4). When fat mass and fat-free
mass were included in the model in place of BMI, only
the former remained as an independent correlate of QUS
parameters, either in the whole cohort or in individuals
with T1DM or T2DM (not shown). When substituting
height and weight for BMI, only weight was an independent
correlate of QUS measures (not shown). The presence/
absence of CVD, DR and CKD and DPN and CAN scores,
when substituted for individual measures of complications,
did not enter the model, except for DPN score when the
analysis was conducted only in patients with T1DM (model
2, data not shown).
4. Discussion
This study provides new information on the correlates of
QUS parameters in subjects with DM by showing an inde-
pendent association with age, male gender, HbA1c, BMI,
and several measures of complications, particularly of DPN
and CAN.
While, as expected, values of BUA, SOS, QUI, and eBMD
were higher in males than in females and decreased with
increasing age; they were similar in patients with T1DM
and T2DM. This somewhat surprising finding might be due
to the fact that T2DM subjects, though older, had shorter
DM duration than those with T1DM, in addition to reflecting
the reduced bone mass observed in T1DM, but not T2DM
individuals [2]. Also, correlates of QUS parameters were
quite similar in patients with T1DM and T2DM, though
there were a few differences (e.g., weaker or no association
with BMI and HbA1c and stronger association with surrogate
measures of peripheral nerve dysfunction in T1DM) which
might reflect the differences in bone microarchitecture
detected in T1DM (involvement of both trabecular and
cortical compartments) [39] versus T2DM (alteration of
the cortical compartment only) [40].
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Table 1: Clinical characteristics of study subjects, overall and by gender.
All Females Males P
N (%) 400 (100.0) 172 (43.0) 228 (57.0)
T1DM, n (%) 80 (20.0) 42 (24.4) 38 (16.7) 0.055
Age, years 61.9± 13.6 63.0± 13.8 61.1± 13.4 0.155
Smoking, n (%) <0.001
Never 237 (59.2) 132 (76.7) 105 (46.1)
Former 105 (26.3) 22 (12.8) 83 (36.4)
Current 58 (14.5) 18 (10.5) 40 (17.5)
Alcohol intake, n (%) <0.001
No 220 (55.0) 133 (77.3) 87 (38.2)
Low 130 (32.5) 39 (22.7) 91 (39.9)
Moderate 42 (10.5) 0 (0.0) 42 (18.4)
High 8 (2.0) 0 (0) 8 (3.5)
PA, n (%) <0.001
Sedentary 73 (18.2) 40 (23.3) 33 (14.5)
Inactive 130 (32.5) 69 (40.1) 61 (26.7)
Active
Low PA 84 (21.0) 31 (18.0) 53 (23.3)
Moderate PA 77 (19.3) 23 (13.4) 54 (23.7)
High PA 36 (9.0) 9 (5.2) 27 (11.8)
Upper body muscle strength, N 221.7± 92.7 157.3± 49.1 270.1± 88.2 <0.001
Lower body muscle strength, N 135.5± 62.8 95.7± 39.4 164.8± 60.7 <0.001
VO2max, ml/min/kg 35.3± 12.1 33.3± 12.6 36.0± 11.8 0.182
Family history of DM, n (%) 173 (43.3) 71 (41.3) 102 (44.7) 0.490
Duration of DM, years 15.6± 10.0 16.7± 10.3 14.7± 9.7 0.048
HbA1c, % 7.15± 1.44 7.24± 1.41 7.09± 1.46 0.313
Glucose, mmol/l 8.59± 3.51 8.39± 3.35 8.74± 3.63 0.323
BMI, kg/m2 28.8± 5.7 29.57± 6.83 28.23± 4.62 0.020
Fat mass, % 29.6± 10.0 37.00± 7.35 24.09± 7.86 <0.001
Fat free mass, kg 55.2± 11.2 45.50± 6.66 62.44± 7.95 <0.001
Waist circumference, cm 97.5± 13.9 94.16± 14.57 100.07± 12.90 <0.001
Triglycerides, mmol/l 1.65± 1.06 1.90± 0.63 1.99± 0.70 0.016
Total cholesterol, mmol/l 4.77± 0.99 4.98± 0.95 4.61± 0.99 <0.001
HDL cholesterol, mmol/l 1.28± 0.37 1.43± 0.37 1.16± 0.32 <0.001
LDL cholesterol, mmol/l 2.82± 0.98 2.91± 0.90 2.75± 1.04 0.097
SBP, mmHg 135.0± 17.2 137.35± 18.58 133.22± 15.81 0.017
DBP, mmHg 78.7± 8.9 78.95± 9.77 78.51± 8.23 0.622
Carotid IMT, mm 1.01± 0.16 0.98± 0.17 1.02± 0.16 0.025
ABI 0.89± 0.15 0.87± 0.15 0.91± 0.15 0.019
Uric acid, μmol/l 294.1± 99.7 267.1± 101.6 312.7± 93.9 <0.001
Plasma nitrogen, mmol/l 16.9± 7.1 17.2± 7.7 16.6± 6.5 0.448
Serum creatinine, μmol/l 99.3± 35.1 89.7± 30.5 106.6± 36.6 <0.001
eGFR, ml/min/1.73m2 68.3± 20.2 65.1± 20.0 70.7± 20.1 0.006
ACR, mg/g 58.6± 65.5 56.1± 79.9 60.5± 52.2 0.507
PMN distal latency, m/s 4.98± 0.65 4.80± 0.58 5.12± 0.67 <0.001
PMN amplitude, mV 3.57± 1.35 3.62± 1.25 3.53± 1.42 0.480
PMN conduction velocity, m/s 44.8± 4.3 45.6± 3.7 44.2± 4.6 0.002
SSN distal latency, m/s 3.29± 0.72 3.19± 0.66 3.36± 0.75 0.018
SSN amplitude, mV 11.6± 8.0 11.9± 8.2 11.4± 8.0 0.560
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Table 1: Continued.
All Females Males P
SSN conduction velocity, m/s 39.5± 11.4 40.0± 11.5 39.2± 11.3 0.496
VPT malleolus, mV 25.9± 13.9 25.0± 13.7 26.6± 14.1 0.262
VPT hallux, mV 20.8± 13.7 20.0± 13.3 21.5± 14.0 0.296
Resting HR, beats/min 66.9± 10.1 69.0± 9.3 65.4± 10.5 0.001
HR response to deep breathing, EI ratio 1.24± 0.16 1.24± 0.15 1.24± 0.16 0.818
HR response to cough test, CT ratio 1.22± 0.15 1.20± 0.16 1.24± 0.15 0.027
HR response to standing, 30 : 15 ratio 1.14± 0.13 1.13± 0.12 1.15± 0.13 0.105
SBP response to standing, Δ(mmHg) 4.92± 6.48 5.39± 6.81 4.56± 6.22 0.214
CVD, n (%) 51 (12.8) 11 (6.4) 40 (17.5) 0.001
CKD, n (%) <0.0001
No 237 (59.3) 100 (58.1) 137 (60.1)
Albuminuria alone 54 (13.5) 13 (7.6) 41 (18.0)
Reduced eGFR alone 68 (17.0) 42 (24.4) 26 (11.4)
Both 41 (10.2) 17 (9.9) 24 (10.5)
DR, n (%) 0.317
No 262 (65.5) 107 (62.2) 155 (68.0)
Nonadvanced 63 (15.7) 27 (15.7) 36 (15.8)
Advanced 75 (18.8) 38 (22.1) 37 (16.2)
DPN, n (%) <0.0001
No 117 (29.2) 51 (29.6) 66 (29.0)
Polyneuropathy
Possible 53 (13.2) 28 (16.3) 25 (11.0)
Probable 19 (4.8) 16 (9.3) 3 (1.3)
Confirmed 153 (38.2) 68 (39.5) 85 (37.3)
Subclinical 35 (8.8) 8 (4.7) 27 (11.8)
Focal or multifocal neuropathy 15 (3.8) 1 (0.6) 14 (6.1)
Diabetes-associated neuropathy 8 (2.0) 0 (0.0) 8 (3.5)
CAN, n (%) 0.817
No 267 (66.8) 114 (66.3) 153 (67.1)
Borderline 40 (10.0) 15 (8.7) 25 (11.0)
Yes 93 (23.2) 43 (25.0) 50 (21.9)
T1DM= type 1 DM; PA = physical activity; VO2max =maximal oxygen consumption; HbA1c = hemoglobin A1c; BMI = body mass index; SBP = systolic blood
pressure; DBP = diastolic blood pressure; IMT = intima-media thickness; ABI = ankle-brachial index; eGFR = estimated glomerular filtration rate;
ACR = albumin : creatinine ratio; PMN peroneal motor nerve; SSN = sural sensory nerve; VPT = vibration perception threshold; HR = heart rate;
EI = expiration-to-inspiration; CT = cough test; CVD= cardiovascular disease; CKD= chronic kidney disease; DPN= diabetic peripheral neuropathy;
CAN= cardiac autonomic neuropathy.
Table 2: QUS values of study subjects, overall and by gender and type of DM.
QUS parameters All Females Males P T1DM T2DM P
BUA, dB/MHz 71.6± 22.1 62.6± 22.1 78.3± 19.5 <0.0001 71.5± 24.9 71.6± 21.4 0.964
SOS, m/s 1541± 80 1527.3± 114.5 1551.8± 33.4 0.002 1548.6± 38.9 1539.3± 87.4 0.354
QUI 92.0± 22.9 84.9± 23.1 97.3± 21.3 <0.0001 93.3± 25.8 91.6± 22.2 0.561
T-score −0.80± 1.33 −1.06± 1.38 −0.61± 1.27 0.001 −0.69± 1.53 −0.83± 1.28 0.376
Z-score 0.19± 1.28 0.25± 1.36 0.16± 1.24 0.476 −0.10± 1.46 0.27± 1.23 0.028
eBMD, g/cm2 0.50± 0.15 0.45± 0.16 0.54± 0.13 <0.0001 0.50± 0.19 0.50± 0.14 0.915
T-score −0.83± 1.32 −1.09± 1.38 −0.63± 1.25 <0.0001 −0.70± 1.53 −0.86± 1.27 0.324
Z-score 0.20± 1.28 0.23± 1.37 0.18± 1.23 0.682 −0.08± 1.45 0.27± 1.23 0.033
QUS = quantitative ultrasound; DM= diabetes mellitus; T1DM= type 1 DM; T2DM= type 2 DM; BUA= broadband ultrasound attenuation; SOS = speed of
sound; QUI = quantitative ultrasound index; eBMD= estimated bone mineral density.
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Table 3: Univariate correlations between QUS parameters and CVD risk factors and measures of complications (Spearman’s rho).
Variable
BUA SOS QUI eBMD
r P r P r P r P
Age −0.176 <0.0001 −0.261 <0.0001 −0.232 <.00001 −0.225 <0.0001
Upper body strength 0.287 <0.0001 0.234 <0.0001 0.261 <0.0001 0.259 <0.0001
Lower body strength 0.288 <0.0001 0.252 <0.0001 0.271 <0.0001 0.273 <0.0001
Vo2max 0.289 <0.0001 0.242 <0.0001 0.258 <0.0001 0.262 <0.0001
DM duration −0.129 0.010 −0.070 0.162 −0.100 0.047 −0.092 0.068
HbA1c 0.055 0.273 0.104 0.038 0.087 0.083 0.089 0.075
Glucose 0.047 0.349 0.048 0.341 0.051 0.310 0.051 0.314
BMI 0.194 <0.0001 0.129 0.010 0.174 <0.0001 0.174 <0.0001
Fat mass −0.087 0.084 −0.051 0.315 −0.051 0.307 −0.060 0.229
Fat-free mass 0.386 <0.0001 0.278 <0.0001 0.328 <0.0001 0.336 <0.0001
Waist circumference 0.248 <0.0001 0.160 0.001 0.212 <0.0001 0.217 <0.0001
Triglycerides 0.162 0.001 0.094 0.060 0.133 0.008 0.137 0.006
Total cholesterol −0.053 0.292 −0.019 0.713 −0.027 0.597 −0.028 0.578
HDL cholesterol −0.251 <0.0001 −0.182 <0.0001 −0.217 <0.0001 −0.217 <0.0001
LDL cholesterol −0.003 0.947 0.026 0.600 0.019 0.704 0.017 0.736
SBP −0.055 0.274 −0.090 0.073 −0.072 0.151 −0.069 0.169
DBP 0.001 0.984 −0.013 0.793 0.001 0.981 0.002 0.975
Carotid IMT 0.030 0.548 −0.030 0.556 −0.005 0.915 −0.003 0.958
ABI 0.084 0.093 0.107 0.034 0.097 0.052 0.093 0.063
Uric acid 0.166 0.001 0.112 0.026 0.139 0.005 0.132 0.008
Plasma nitrogen −0.056 0.263 −0.078 0.122 −0.085 0.088 −0.072 0.150
Serum creatinine 0.077 0.126 0.092 0.069 0.086 0.088 0.088 0.082
eGFR 0.070 0.161 0.103 0.041 0.102 0.041 0.096 0.057
ACR 0.095 0.057 0.115 0.022 0.107 0.033 0.116 0.021
PMN distal latency 0.069 0.167 0.062 0.215 0.063 0.209 0.075 0.134
PMN amplitude 0.072 0.150 0.107 0.034 0.101 0.045 0.091 0.068
PMN conduction velocity 0.015 0.771 0.021 0.684 0.032 0.526 0.019 0.710
SSN distal latency 0.120 0.017 0.109 0.029 0.113 0.024 0.113 0.025
SSN amplitude 0.096 0.055 0.133 0.008 0.133 0.008 0.120 0.016
SSN conduction velocity 0.034 0.494 0.053 0.294 0.060 0.235 0.046 0.358
VPT malleolus −0.047 0.346 −0.073 0.144 −0.062 0.218 −0.050 0.318
VPT hallux −0.045 0.365 −0.071 0.156 −0.061 0.221 −0.050 0.319
Resting HR −0.080 0.109 −0.085 0.090 −0.089 0.075 −0.092 0.067
EI ratio 0.056 0.273 0.069 0.175 0.071 0.165 0.069 0.178
CT ratio 0.099 0.052 0.123 0.015 0.119 0.019 0.123 0.015
30 : 15ratio 0.114 0.025 0.181 <0.0001 0.161 0.001 0.157 0.002
Systolic BP fall 0.031 0.546 −0.011 0.822 0.005 0.914 0.004 0.938
BUA — — 0.850 <0.0001 0.935 <0.0001 0.930 <0.0001
SOS 0.850 <0.0001 — — 0.973 <0.0001 0.973 <0.0001
QUI 0.935 <0.0001 0.973 <0.0001 — — 0.995 <0.0001
eBMD 0.930 <0.0001 0.973 <0.0001 0.995 <0.0001 — —
QUS = quantitative ultrasound; CVD= cardiovascular disease; BUA = broadband ultrasound attenuation; SOS = speed of sound; QUI = quantitative ultrasound
index; eBMD= estimated bone mineral density; DM= diabetes mellitus; VO2max =maximal oxygen consumption; HbA1c = hemoglobin A1c; BMI = body mass
index; SBP = systolic blood pressure; DBP = diastolic blood pressure; IMT = intima-media thickness; ABI = ankle-brachial index; eGFR = estimated glomerular
filtration rate; ACR = albumin : creatinine ratio; PMN peroneal motor nerve; SSN = sural sensory nerve; VPT = vibration perception threshold; HR = heart rate;
EI = expiration : inspiration; CT = cough test.
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The strong association between BMI and QUS parame-
ters is consistent with a large body of evidence showing that
DXA-derived BMD is positively related to BMI in the general
population [41] and in diabetic patients [2, 42], an effect
likely mediated by mechanical loading on bone [22], and
inversely related to fracture risk [43], though this relation
varies according to the fracture site [44]. Indeed, the
results of a large meta-analysis have indicated that the
relationship between BMI and fracture risk is significantly
modified by the interaction between BMI and BMD [45]
and a recent study has found that the majority of BMI
effect on fracture risk is not direct but rather mediated
by femoral neck BMD [46]. Our findings are also consistent
with the correlation between BMI and QUS parameters
observed in previous reports [47–49], though other studies
failed to detect an association of SOS [50] or all three QUS
measures [51] with BMI.
The observation that QUS parameters were positively
related also to waist circumference, fat mass, triglycerides
and, inversely, HDL cholesterol, but not mass free-mass
(except than in univariate analysis), seems to suggest that
adiposity, rather than lean mass, is protective for the skele-
ton. Though fat mass and lean mass both cause mechanical
loading [52], the relative effect of these two determinants
Table 4: Independent correlates of QUS parameters by multiple regression analysis with stepwise variable selection, in the whole cohort and
in patients with T1DM and T2DM separately.
Variable
BUA SOS QUI eBMD
Beta P Beta P Beta P Beta P
Whole cohort
Age −0.284 0.001 −0.344 <0.0001 −0.342 <0.0001 −0.236 0.001
Male gender 0.356 <0.0001 0.191 0.011 0.245 0.001 0.244 0.001
HbA1c — — 0.169 0.047 — — 0.148 0.043
BMI 0.290 <0.0001 0.334 <0.0001 0.355 <0.0001 0.299 <0.0001
PMN amplitude 0.153 0.035 0.181 0.018 0.160 0.031 0.190 0.012
SSN amplitude 0.228 0.017 0.168 0.028 0.185 0.016 0.180 0.018
VPT hallux — — 0.329 0.009 0.259 0.015 — —
Resting HR — — −0.192 0.012 — — −0.196 0.010
HR response to cough test (CT ratio) 0.143 0.050
HR response to standing (30 : 15 ratio) — — — — 0.176 0.022 0.139 0.021
T1DM
Age −0.450 0.001 −0.597 <0.0001 −0.462 0.001 −0.319 0.020
Male gender 0.296 0.007 — — 0.230 0.032 0.258 0.019
HbA1c — — — — — — — —
BMI 0.371 0.007 — — 0.288 0.018 0.395 0.002
PMN amplitude 0.679 <0.0001 0.510 0.002 0.547 0.001 0.739 <0.0001
SSN amplitude 0.296 0.041 — — 0.299 0.042 — —
VPT hallux 0.502 0.007 0.476 0.023 0.406 0.031 0.410 0.040
Resting HR — — — — — — — —
HR response to cough test (CT ratio) 0.251 0.027
HR response to standing (30 : 15 ratio) — — — — — — 0.246 0.024
T2DM
Age — — — — −0.134 0.014 −0.169 0.003
Male gender 0.396 <0.0001 0.218 <0.0001 0.283 <0.0001 0.272 <0.0001
HbA1c 0.113 0.029 0.140 0.012 0.136 0.011 0.119 0.030
BMI 0.344 <0.0001 0.392 <0.0001 0.414 <0.0001 0.409 <0.0001
PMN amplitude 0.175 0.048 0.128 0.044 0.205 0.023 0.132 0.034
SSN amplitude — — 0.166 0.011 0.215 <0.0001 0.163 0.011
VPT hallux — — — — — — — —
Resting HR — — −0.120 0.032 — — −0.114 0.037
HR response to cough test (CT ratio) — — 0.204 0.019 — — — —
HR response to standing (30 : 15 ratio) — — — — — — — —
QUS = quantitative ultrasound; T1DM= type 1 DM; T2DM= type 2 DM; BUA= broadband ultrasound attenuation; SOS = speed of sound; QUI = quantitative
ultrasound index; eBMD= estimated bone mineral density; HbA1c = hemoglobin A1c; BMI = body mass index; PMN peroneal motor nerve; SSN = sural sensory
nerve; VPT = vibration perception threshold; HR = heart rate.
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of body composition on BMD still remains controversial
[53]. Our results seem to be at odds with several studies
showing that lean mass, but not fat mass, is positively asso-
ciated with BMD in men [54], women [55], and both [56].
However, a recent meta-analysis showed that the overall
impact of lean mass on femoral neck BMD is higher than
that of fat mass and that this is the case in men and pre-
menopausal women, whereas in postmenopausal women
the effects of lean mass and fat mass are similar [57]. In
addition, our findings do not support a detrimental effect
of adiposity on bone health through the associated inflamma-
tion [23], though inflammatory markers were not assessed in
our study.
Another important observation of this study is the asso-
ciation of QUS parameters with measures of peripheral nerve
dysfunction, both somatic and autonomic, including PMN
and SSN amplitude, VPT, HR response to cough test and
standing, and resting HR. Though the latter parameter is
not a specific index of CAN, association with QUS measures
was independent of several factors which are known to influ-
ence HR, such as BMI, PA level, and VO2max. The finding
that QUS parameters were associated with peripheral nerve
function is in agreement with a previous report from the
Health, Aging, and Body Composition Study, showing that
peripheral nerve dysfunction was related to lower hip BMD
and calcaneal QUS in older adults [58]. It is also in keeping
with the higher prevalence of neuropathy (52% versus 22%)
in subjects with low versus normal BMD [59] and with the
independent association of neuropathy with reduced BMD
in the affected limbs as well as elsewhere [15] in patients with
T1DM. Thus, our data strongly support the concept that
DPN may contribute to bone abnormalities and increased
fracturative risk in diabetes.
Strengths of the study are the numerous risk factors and
measures of complications considered as potential correlates
of QUS parameters. Limitations include the cross-sectional
design of the study and the relatively low number of patients
with T1DM.Moreover, our work might be limited by the lack
of a control group, though the comparison with healthy sub-
jects was beyond the scope of our investigation, which was
aimed at identifying QUS correlates in diabetic subjects with
various degrees of complications.
5. Conclusions
In conclusion, our data indicate that peripheral nerve
dysfunction, both somatic and autonomic, is associated
with worse QUS parameters, thus suggesting that this
complication may contribute to increased fracture risk in
diabetes, possibly by impairing bone quality. Conversely,
the positive relation of QUS measures with adiposity needs
further investigation.
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